WALTHAM, Mass., May 29, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a late-stage oncology company, announced today that updated

Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women show that the combination of two cancer drugs, everolimus and exemestane, significantly improves bone strength and reduces the chances of cancer spreading (metastasising) in the bone.

Preoperative treatment with aromatase inhibitors increases the likelihood that postmenopausal women with estrogen receptor-positive breast cancer will be able to have breast-conserving surgery rather than a mastectomy.

It kills wives, daughters, moms, and friends. One out of every 36 women die of breast cancer. Among postmenopausal women with hormone receptor-positive breast cancer, their risk of dying from breast cancer increases with age.

Exemestane, a drug that is thought to prevent breast cancer, steadily lowers that levels of ‘good’ cholesterol in women taking the agent.